tetano
Editor, Senior Moderator
Biomed Pharmacother
. 2024 Mar 13:173:116231.
doi: 10.1016/j.biopha.2024.116231. Online ahead of print. Emerging role of N6-methyladenosine RNA modification in regulation of SARS-CoV-2 infection and virus-host interactions
Jiayi Liu[SUP] 1 [/SUP], Lingli Chen[SUP] 2 [/SUP], Xiongmin Guo[SUP] 1 [/SUP], Bingrong Zhao[SUP] 3 [/SUP], Juan Jiang[SUP] 4 [/SUP]
Affiliations
Since December 2019, the infection caused by Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) has posed an enormous threat to human health security worldwide. Constant mutation of viral genome and varying therapeutic responses of patients infected with this virus prompted efforts to uncover more novel regulators in the pathogenesis. The involvement of N6-methyladenosine, a modified form of RNA, plays a crucial role in viral replication, viral pathogenicity, and intricate signaling pathways connected with immune responses. This review discusses research advances revealing the regulation of the life cycle of SARS-CoV-2 and antiviral responses of host cells by RNA m6A modification, highlights the biological functions of N6-methyladenosine components in SARS-CoV-2 infection and virus-host interactions, and outlines current challenges and future directions for exploring the potential clinical value of m6A modification in COVID-19.
Keywords: COVID-19; Epigenetic transcriptomics; Host cells; N6-methyladenosine (m6A); RNA modification; Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)
. 2024 Mar 13:173:116231.
doi: 10.1016/j.biopha.2024.116231. Online ahead of print. Emerging role of N6-methyladenosine RNA modification in regulation of SARS-CoV-2 infection and virus-host interactions
Jiayi Liu[SUP] 1 [/SUP], Lingli Chen[SUP] 2 [/SUP], Xiongmin Guo[SUP] 1 [/SUP], Bingrong Zhao[SUP] 3 [/SUP], Juan Jiang[SUP] 4 [/SUP]
Affiliations
- PMID: 38484561
- DOI: 10.1016/j.biopha.2024.116231
Since December 2019, the infection caused by Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) has posed an enormous threat to human health security worldwide. Constant mutation of viral genome and varying therapeutic responses of patients infected with this virus prompted efforts to uncover more novel regulators in the pathogenesis. The involvement of N6-methyladenosine, a modified form of RNA, plays a crucial role in viral replication, viral pathogenicity, and intricate signaling pathways connected with immune responses. This review discusses research advances revealing the regulation of the life cycle of SARS-CoV-2 and antiviral responses of host cells by RNA m6A modification, highlights the biological functions of N6-methyladenosine components in SARS-CoV-2 infection and virus-host interactions, and outlines current challenges and future directions for exploring the potential clinical value of m6A modification in COVID-19.
Keywords: COVID-19; Epigenetic transcriptomics; Host cells; N6-methyladenosine (m6A); RNA modification; Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)